Landmark collaboration to commercialise transdermal cannabis technologies

19 June 2019

Little Green Pharma is pleased to announce a collaboration agreement with OBJ. Little Green Pharma and OBJ will contribute equally to the Curtin Research and Development services in Western Australia with the adaptation of the transdermal technology to deliver cannabinoid therapy transdermally, with a view to the joint ownership and commercialisation of the technology.

If the cannabinoid trials at Curtin University are successful in demonstrating that cannabinoids can effectively use OBJ’s micro-array technology:

  • this could result in one of the most advanced and effective medicinal cannabis delivery systems developed in the world, to date; and
  • the OBJ joint venture with Little Green Pharma could rapidly develop both its own products as well as licensing the technology to third parties for rapid distribution worldwide. Little Green Pharma operates from one of the few fully-licensed GMP certified medicinal cannabis manufacturing facilities in Australia.

Little Green Pharma is currently the only Australian medicinal cannabis company producing locally-grown and -manufactured GMP cannabis products for patients. Little Green Pharma cultivates locally grown medicinal cannabis from a secure facility in Western Australia and distributes its products nationally.

For the full media release and to read more about this exciting new partnership please visit: http://www.obj.com.au/wp-content/uploads/2019/06/02115462.pdf

Back to news